The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes

The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes Eric Van Cutsem Oncologist 2004; 9(Suppl 2): 9-15 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the role and evolution of chemotherapy for advanced gastric cancer. Discuss results of phase II trials evaluating taxanes in advanced gastric cancer. Describe the results and clinical implications of a phase III trial of docetaxel, cisplatin, and fluorouracil in advanced gastric cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 25, 2004 Most Recent Review: May 25, 2004* Most Recent Update: May 25, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes.